Nov 09,2023 TOP STORY

Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Better Therapeutics reported financial results for the third quarter 2023. Research and development expenses for the quarter ended September 30, 2023 were $1.8 million, compared to $5.5 million for the same period in 2022. The decrease was primarily due to a $2.0 million decrease in clinical study costs as a result of the completion of the BT-001 pivotal trial in the third quarter of 2022 as well as a $1.8 million decrease in personnel related costs as a result of savings from the restructuring in the first quarter of 2023. Net loss for the quarter ended September 30, 2023 was $5.9 million, compared to $11.4 million for the same period in 2022. Finally, cash and cash equivalents of the Company were reported as $6.6 million on September 30, 2023, compared to $15.7 million on December 31, 2022. During the third quarter, Better Therapeutics announced that the U.S. Food and Drug Administration (FDA) authorized AspyreRx, and the completion of enrollment of 1,000 participants in its real-world evidence program evaluating the long-term effectiveness of AspyreRx in T2D. To support the commercialization of AspyreRx, Better Therapeutics expects to announce a business development partnership by the end of this year, as stated in the press release.

View Analyst & Ambassador Comments
Go to original news
Nov 09,2023 TOP STORY

Kakao Healthcare secures deal to distribute Dexcom G7

Kakao Healthcare, the digital arm of South Korean internet company Kakao Corporation, has signed a local sales agreement with pharmaceutical firm Huons to make Dexcom G7 continuous glucose monitors available across South Korea. The sale of the Dexcom G7, which will begin in the first quarter of next year, is part of Kakao Healthcare's initiative to set up a local digital diabetes management service with Dexcom. To recall, the two companies entered into a global collaboration in June 2023.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 26,2023

Real-world data analysis shows significant improvement in glycaemic management when using a blood glucose monitor connected to the mySugr® app in UK users with type 2 diabetes

Roche announced that real world data shows a significant improvement in glycaemic management when using a blood glucose monitor connected to the mySugr mobile health app in UK users with type 2 diabetes. Previous studies had shown an improvement in people with type 1 diabetes with the use of blood glucose monitors connected with mobile health apps. The aim of this study, currently being presented at the Diabetes UK Professional Conference 2023, was to explore the impact of a blood glucose monitor connected to the mySugr app in UK users with type 2 diabetes, as this population often shows reduced glycaemic outcomes and increased diabetes-related complications. The retrospective analysis looked at 1,229 people from the UK, with both type 1 and type 2 diabetes, who used an Accu-Chek meter connected with the mySugr app. After 4 months of using the mySugr app with a connected blood glucose meter, a statistically significant reduction of 0.44% was observed in the estimated HbA1c in users with type 2 diabetes. A reduction was observed in estimated HbA1c after only one month of use. 

CLINICAL STUDY

#bgm

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023 TOP STORY

Withings Health, Vida Health Partner to Enhance Virtual Cardiometabolic Care

Vida Health, a virtual cardiometabolic care provider and wearables provider Withings Health Solutions has partnered to provide Vida members with remote monitoring devices, including the Withings Body Pro cellular scale and the BPM Connect Pro cellular blood pressure monitor. The collaboration aims to enhance the patient experience by providing Vida members access to high-quality monitoring devices, facilitating meaningful discussions with healthcare providers, and establishing actionable health goals. Vida’s virtual cardiometabolic care solutions serve clients across the United States, offering proven clinical outcomes for various conditions such as obesity, diabetes, hypertension, and more.

COLLABORATION PARTNERSHIP

#connected device

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023 TOP STORY

Welldoc Presents Data Showing Use of Digital Health Tool with AI-coaching Leads to Weight Loss and Improved Health Measures, Adding to Over 75 Publications to Date

Welldoc announced data demonstrating that the use of a digital health application in a virtual program for individuals with type 2 diabetes was associated with significant improvements in weight loss, as well as favorable trends in post-meal blood glucose and systolic blood pressure. The data, which were presented as a clinical research poster at the 18th Annual Cardiometabolic Health Congress in Boston, capture the results of a real-world study in which individuals were given access to the Welldoc App, which provides continuous AI-driven digital coaching designed to support self-management behaviors. Data show that the average weight at the endpoint was significantly lower than the baseline, with over 77% of participants losing an average of 4.8% of their baseline body weight. There were also statistically significant improvements in systolic blood pressure and favorable post-meal blood glucose trends.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023 TOP STORY

Roche Diabetes Care China to Establish the “Chengdu Model” for Digital Diabetes Management

Roche is participating in the China International Important Expo (CIIE) for the sixth consecutive year, demonstrating integrated solutions from Roche Pharmaceuticals and Roche Diagnostics. Roche Diabetes Care demonstrated their latest product solutions, including the ACCU-CHEK® Guide, ACCU-CHEK® Guide Me ACCU-CHEK® Instant Blood Glucose Monitoring Systems, and Sugar Bright digital diabetes management platform. At the CIIE, Roche Diabetes Care signed a strategic cooperation memorandum with Chengdu Eastern New Area Municipal Administration Committee to jointly advance the development of a comprehensive digital chronic disease management demonstration area.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023

Medtronic to announce financial results for its second quarter of fiscal year 2024

Medtronic, a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2024 on Tuesday, November 21, 2023. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com(opens new window). The news release will include summary financial information for the company's second quarter of fiscal year 2024, which ended on Friday, October 27, 2023.

View Analyst & Ambassador Comments
Go to original news
Nov 08,2023

Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

Better Therapeutics announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions and in July 2023 received FDA authorization for AspyreRxTM to treat adults with type 2 diabetes.

View Analyst & Ambassador Comments
Go to original news
Nov 08,2023

Participants In Abbott's Food As Medicine Program Showed Clinically Significant Improvements In Managing Diabetes

A study of Abbott's Healthy Food Rx, a food as medicine program that provides home-delivered medical prescriptions of healthy food to help address diabetes, showed clinically important benefits for people with diabetes. The real-world study, which was conducted by the Public Health Institute's Center for Wellness and Nutrition (PHI CWN) in an active community clinic over a 12-month period, found that Healthy Food Rx participants had lower A1C levels, improved diabetes self-management, and improved overall diet quality and food security. In 2021, Abbott and its foundation the Abbott Fund launched the Healthy Food Rx program in Stockton, Calif., where 60% of the population has diabetes or prediabetes. The program, part of the company's broader Future Well™Communities initiative, brings together Stockton-based organizations to help individuals living with diabetes by delivering free recipe-based food boxes to approximately 450 participants' homes and providing hands-on education about managing their diabetes through nutrition. During this study, participants with uncontrolled diabetes (baseline A1C values greater than 7.0%) saw their A1C levels decrease by 0.80%, on average. The number of participants who rated their ability to self-manage their diabetes grew significantly through the program.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES